Regarding your editorial “Joe Biden’s Insulin Fictions” (March 2): Either it is a fiction that insulin prices are coming down, or it is a fiction that drug makers will “spread the costs of cheaper insulin in other products they sell.”

If your claim is correct that most drug makers won’t actually have to lower the price of insulin, then they lose nothing. Ergo, there will be no price increases elsewhere to compensate for it. If, however, drug makers do lower their insulin prices across the board, then I suppose President Biden and the Democrats are taking a lap to celebrate what is almost certainly a Pyrrhic victory, because other prices will have to be raised. But it can’t be both.

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8